Evidence map›Paper›PMID 36985552›Full record

ArticleMolecules (Basel, Switzerland)2023

Poly-

Shuangling Chen, Meng Liang, Chengli Wu, Xiaoyi Zhang, Yuji Wang, Ming Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Response surface methodology to optimize theJournal of food science and technology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shuangling ChenSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-2294-2034
Meng LiangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Chengli WuSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Xiaoyi ZhangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Yuji WangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-3842-7627
Ming ZhaoSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Capital Medical University · CN

Funding

Capital Medical University PYZ2017107Capital Medical University XSKY2015060Capital Medical University XSKY202105Ministry of Education 3500-1205080302Ministry of Science and Technology of the People's Republic of China 0001-56105602
6 · The paper itself

Abstract

The most concerning adverse effects of thrombolytic agents are major bleeding and intracranial hemorrhage due to their short half-life, low fibrin specificity, and high dosage. To alleviate bleeding side effects during thrombolytic therapy which would bring about the risk of aggravation, we try to find a novel biodegradable delivery nanosystem to carry drugs to target the thrombus, reduce the dosage of the drug, and system side effects. A novel urokinase/poly-

Indexed as

ThrombosisAnimalsFibrinolytic AgentsOligopeptidesRatsThrombolytic TherapyUrokinase-Type Plasminogen Activatorarginyl-glycyl-aspartyl-serineFibrinolytic AgentsOligopeptidesUrokinase-Type Plasminogen Activatornano delivery systemRGDStargetedthrombolyticurokinase

Identifiers

PMID36985552
PMCPMC10054729
OpenAlexW4324067010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.